Walleye Capital
AVXL icon

Walleye Capital’s Anavex Life Sciences AVXL Stock Holding History

Walleye Capital’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$782 Sell
302
-96
-24% -$284 ﹤0.01% 4612
2026
Q1 		$1.22K Sell
398
-5,611
-93% -$24.3K ﹤0.01% 4257
2025
Q4 		$21.4K Buy
+6,009
New +$36.8K ﹤0.01% 4239

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Walleye Capital's AVXL Position: Q2 2026 in Review

Walleye Capital reduced its Anavex Life Sciences (AVXL) stake by 24% in Q2 2026, selling an estimated $284 and leaving 302 shares worth $782. The position accounts for ﹤0.01% of the portfolio, ranked #4612.

Walleye Capital first reported a position in AVXL in Q4 2025 and has held it in 3 quarters since. The position peaked at $21.4K in Q4 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Walleye Capital held 302 shares of Anavex Life Sciences worth $782 as of Q2 2026.
  • Walleye Capital sold 96 Anavex Life Sciences shares in Q2 2026, an estimated $284.
  • Anavex Life Sciences made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4612 holding.
  • Walleye Capital first reported a position in Anavex Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • Walleye Capital's Anavex Life Sciences position peaked at $21.4K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.